Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tissue Regenix taps wound care rival KCI for latest US team member

This article was originally published in Clinica

Executive Summary

York, UK-based regenerative medicine specialist Tissue Regenix has appointed Tim Buechner vice-president of operations for its new US subsidiary. Mr Buechner joins from advanced wound care firm KCI, where he was senior director of commercial and sales operations. His 25-year career stretches across different disciplines including contracting, revenue cycle, sales operations, finance and project management. He will work with Greg Bila, president of Tissue Regenix’s US subsidiary in San Antonio, Texas, to expand the company’s activities on that side of the Atlantic. Tissue Regenix has developed the dCell decellularization process that removes DNA and other cellular material from animal and human tissue. The remaining acellular tissue scaffold can be used to repair diseased or worn out body parts. In addition to wound care, the company is focusing on cardiac, vascular and orthopedic applications of its technology.

You may also be interested in...

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts